8-KLeadership ChangesMaterial AgreementsExhibits & Filings

PFIZER INC 8-K Report, Material Agreement (Aug 3, 2006)

Filed August 3, 2006For Securities:PFE

Summary

Pfizer Inc. announced a significant leadership transition, appointing Jeffrey B. Kindler as Chief Executive Officer effective July 31, 2006. This change sees Henry A. McKinnell transition from CEO to Chairman of the Board, a role he will hold until his retirement on February 28, 2007. The filing also details new compensation arrangements for Mr. Kindler, including a base salary increase, a higher target annual bonus, and a stock option grant. Investors should note the strategic implications of this CEO change and the associated compensation packages. The details surrounding Mr. Kindler's stock option grant, particularly the vesting conditions tied to stock price performance, suggest a focus on long-term shareholder value creation. The transition plan for Dr. McKinnell indicates a structured handover, with the company indicating that his departure benefits are expected to align with his existing employment agreement.

Key Highlights

  • 1Jeffrey B. Kindler appointed Chief Executive Officer (CEO) effective July 31, 2006.
  • 2Henry A. McKinnell to remain Chairman of the Board until February 28, 2007, after which he will retire.
  • 3Mr. Kindler's base salary increased from $947,500 to $1,350,000.
  • 4Mr. Kindler's target annual bonus increased from 65% to 150% of base salary.
  • 5Mr. Kindler granted an option to purchase 500,000 shares of Pfizer common stock at $26.29 per share.
  • 6Stock option has a five-year vesting period and is contingent on the stock price exceeding 150% of the exercise price for 20 consecutive trading days.
  • 7New compensation arrangements for Mr. Kindler include provisions related to performance-contingent share and performance-share awards, tied to total shareholder return relative to peer companies.

Frequently Asked Questions

This 8-K filing announces a material change in Pfizer's leadership, specifically the appointment of a new Chief Executive Officer, Jeffrey B. Kindler, and details his new compensation arrangements.

Jeffrey B. Kindler has been appointed CEO effective July 31, 2006. Henry A. McKinnell, the outgoing CEO, will continue as Chairman of the Board until February 28, 2007, when he will retire from the Board.

Mr. Kindler's base salary was increased to $1,350,000, and his target annual bonus increased to 150% of base salary. He was also granted an option for 500,000 shares at $26.29 per share, with specific performance-based vesting conditions.

Yes, the stock option is exercisable only after the fifth anniversary of the grant date, and only if the average closing price of Pfizer's common stock for 20 consecutive trading days exceeds 150% of the exercise price ($26.29).

The company is negotiating the definitive terms of Dr. McKinnell's departure as a principal officer. It is expected that any payments and benefits will not exceed what he would be entitled to under his existing employment agreement if terminated without cause as of February 28, 2007. The definitive terms will be disclosed in a subsequent filing.